Abstract
The short-term antianginal efficacy of a slow-release 50mg isosorbide-5-mononitrate (IS-5-MN) capsule preparation was assessed in a randomised, double-blind, placebo-controlled, crossover study in 20 patients. The primary target parameter was the time to moderate angina (time to P2) occurring during ergometric exercise testing commencing 30 minutes after intake of the drug. The 50mg IS-5-MN sustained-release preparation increased the time until moderate angina occurred by 75.9 seconds compared with placebo. Mean time to moderate angina was 703.3 seconds in sequence group 1, 30 minutes after intake of IS-5-MN on the first day, while mean duration of exercise was 641.6 seconds on the second day, when placebo medication was applied. Patients of sequence group 2 stopped exercising after an average 590.6 seconds the first day (placebo) and after 680.7 seconds the second day (IS-5-MN). These findings indicate that the antianginal activity of slow-release IS-5-MN is present 30 minutes after intake of the drug.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
